Literature DB >> 24613919

MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2.

Weiping Li1, Zhongyu Liu2, Li Chen2, Li Zhou3, Yuanqing Yao4.   

Abstract

Our previous study found that runt-related transcription factor-2 (RUNX2) was upregulated in human epithelial ovarian cancer (EOC) tissues and may be involved in tumor progression and prognosis. The aim of this study was to investigate the mechanism by which RUNX2 is aberrantly expressed in EOC. We firstly confirmed that miRNA-23b directly targets RUNX2 in EOC. Then, ectopic expression of miR-23b significantly inhibited ovarian cancer cell proliferation and tumorigenicity by regulating the expression of RUNX2. Furthermore, the down-regulation of miR-23b was significantly correlated with tumor aggressiveness and poor prognosis of patients with EOC. Collectively, miR-23b may function as tumor suppressor through inhibiting the upregulation of RUNX2, and may be a potential prognostic marker for EOC.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Clinicopathological feature; Epithelial ovarian cancer; MicroRNA-23b; Overall survival; Progression-free survival; Runt-related transcription factor-2

Mesh:

Substances:

Year:  2014        PMID: 24613919     DOI: 10.1016/j.febslet.2014.02.055

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer.

Authors:  Chang-Hua Kou; Tian Zhou; Xi-Lin Han; Hui-Jie Zhuang; Hai-Xin Qian
Journal:  Oncol Lett       Date:  2016-10-14       Impact factor: 2.967

Review 2.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

3.  Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer.

Authors:  Gang Ma; Weijie Dai; Aiyu Sang; Xiaozhong Yang; Chengcheng Gao
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

4.  MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner.

Authors:  Huixiao Chen; Ling Zhang; Lili Zhang; Jing Du; Hongying Wang; Bin Wang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

5.  miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage.

Authors:  Quanbo Ji; Xiaojie Xu; Yameng Xu; Zhongyi Fan; Lei Kang; Ling Li; Yingchun Liang; Jing Guo; Tian Hong; Zhongli Li; Qiang Zhang; Qinong Ye; Yan Wang
Journal:  J Mol Med (Berl)       Date:  2016-01-27       Impact factor: 4.599

6.  microRNA-23b regulates the expression of inflammatory factors in vascular endothelial cells during sepsis.

Authors:  Ming Wu; Jian-Teng Gu; Bin Yi; Zhong-Zhi Tang; Guo-Cai Tao
Journal:  Exp Ther Med       Date:  2015-01-28       Impact factor: 2.447

7.  MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2.

Authors:  Shujun Feng; Wenjing Pan; Ye Jin; Jianhua Zheng
Journal:  Tumour Biol       Date:  2014-09-02

8.  MicroRNA-23b Inhibits the Proliferation and Migration of Heat-Denatured Fibroblasts by Targeting Smad3.

Authors:  Xipeng Zhang; Jie Yang; Jiming Zhao; Pihong Zhang; Xiaoyuan Huang
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

9.  Predicting MicroRNA Biomarkers for Cancer Using Phylogenetic Tree and Microarray Analysis.

Authors:  Hsiuying Wang
Journal:  Int J Mol Sci       Date:  2016-05-19       Impact factor: 5.923

10.  Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Hiroki Takeshita; Mahito Miyamae; Takuma Ohashi; Wataru Okajima; Taisuke Imamura; Jun Kiuchi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.